Carisma Therapeutics
Delivering macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
Launch date
Employees
Market cap
$42.4m
Enterprise valuation
$10m (Public information from Sep 2024)
Share price
$0.981 CARM
Philadelphia Pennsylvania (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenues | - | - | 9.8m | 14.9m | 22.5m | 16.8m |
| % growth | - | - | - | 52 % | 51 % | (25 %) |
| EBITDA | (27.9m) | (40.1m) | (54.3m) | (85.8m) | - | - |
| % EBITDA margin | - | - | (552 %) | (575 %) | - | - |
| Profit | (28.3m) | (40.8m) | (61.2m) | (86.9m) | - | - |
| % profit margin | - | - | (623 %) | (582 %) | - | - |
| R&D budget | 23.3m | 34.4m | 56.6m | 74.1m | - | - |
| R&D % of revenue | - | - | 576 % | 497 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
$53.0m | Series A | ||
$6.0m | Series A | ||
$47.0m | Series B | ||
$12.0m Valuation: $235m -8.4x EV/LTM EBITDA | Series B | ||
* | $30.0m | Series C | |
| Total Funding | $148m | ||
